Paper28747713
Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Kumari S and 4 others. Sci Rep, 2017. Cited by 124 papers, by iCite.
Cite this record
ConductScience Library. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Papers, record 28747713. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28747713
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Alkylating | Major topic |
| Blood-Brain Barrier | Major topic |
| Drug Carriers | Major topic |
| Glioma | Major topic |
| Lactoferrin | Major topic |
| Temozolomide | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Mice | |
| Nanoparticles | |
| Treatment Outcome |
Source PubMed
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26461917 | Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats. | PLoS One | 2015 | https://conductscience.org/library/papers/26461917 | PubMed |
| 2 | 27864056 | Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy. | Int J Biol Macromol | 2017 | https://conductscience.org/library/papers/27864056 | PubMed |
| 3 | 10536244 | Preparation and in vitro characterization of HSA-mPEG nanoparticles. | Int J Pharm | 1999 | https://conductscience.org/library/papers/10536244 | PubMed |
| 4 | 19149575 | Recent approaches to improve the antitumor efficacy of temozolomide. | Curr Med Chem | 2009 | https://conductscience.org/library/papers/19149575 | PubMed |
| 5 | 20925470 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. | Expert Rev Neurother | 2010 | https://conductscience.org/library/papers/20925470 | PubMed |
| 6 | 21988793 | Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. | Mol Cancer | 2011 | https://conductscience.org/library/papers/21988793 | PubMed |
| 7 | 20680664 | Structural characteristic, pH and thermal stabilities of apo and holo forms of caprine and bovine lactoferrins. | Biometals | 2010 | https://conductscience.org/library/papers/20680664 | PubMed |
| 8 | 10601688 | Desolvation process and surface characterisation of protein nanoparticles. | Int J Pharm | 2000 | https://conductscience.org/library/papers/10601688 | PubMed |
| 9 | 26325605 | Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. | Cancer Lett | 2015 | https://conductscience.org/library/papers/26325605 | PubMed |
| 10 | 26186026 | In vitro and in vivo effect of human lactoferrin on glioblastoma growth. | J Neurosurg | 2015 | https://conductscience.org/library/papers/26186026 | PubMed |
| 11 | 27151598 | Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles. | Sci Rep | 2016 | https://conductscience.org/library/papers/27151598 | PubMed |
| 12 | 18653231 | Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. | Biomaterials | 2008 | https://conductscience.org/library/papers/18653231 | PubMed |
| 13 | 26149889 | Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex. | Mol Pharm | 2015 | https://conductscience.org/library/papers/26149889 | PubMed |
| 14 | 26149830 | Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. | Drug Metab Dispos | 2015 | https://conductscience.org/library/papers/26149830 | PubMed |
| 15 | 22122467 | Temozolomide: mechanisms of action, repair and resistance. | Curr Mol Pharmacol | 2012 | https://conductscience.org/library/papers/22122467 | PubMed |
| 16 | 25088498 | Carboplatin loaded protein nanoparticles exhibit improve anti-proliferative activity in retinoblastoma cells. | Int J Biol Macromol | 2014 | https://conductscience.org/library/papers/25088498 | PubMed |
| 17 | 1739631 | Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). | Br J Cancer | 1992 | https://conductscience.org/library/papers/1739631 | PubMed |
| 18 | 17048089 | Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. | J Biomed Sci | 2007 | https://conductscience.org/library/papers/17048089 | PubMed |
| 19 | 25950506 | Drug-Induced Self-Assembly of Modified Albumins as Nano-theranostics for Tumor-Targeted Combination Therapy. | ACS Nano | 2015 | https://conductscience.org/library/papers/25950506 | PubMed |
| 20 | 25906059 | Chemotherapy in glioma. | CNS Oncol | 2015 | https://conductscience.org/library/papers/25906059 | PubMed |
Cited by69
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 124 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941995 | Lactoferrin and Nanotechnology: New Perspectives and Therapeutic Applications for This Multifunctional Protein. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941995 | PubMed |
| 42828315 | Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42828315 | PubMed |
| 42740496 | Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy. | CNS Neurosci Ther | 2026 | https://conductscience.org/library/papers/42740496 | PubMed |
| 42683315 | The ERK MAPK pathway in mesenchymal glioblastoma: tumorigenesis, microenvironmental reprogramming, and the therapeutic promise of RAS(ON) multi-selective inhibition. | Front Mol Neurosci | 2026 | https://conductscience.org/library/papers/42683315 | PubMed |
| 42380984 | BBB-aware stimuli-responsive and biomimetic nanomedicines for glioblastoma. | Chin Neurosurg J | 2026 | https://conductscience.org/library/papers/42380984 | PubMed |
| 41872417 | Design, Optimization, and In Vitro Evaluation of Lactoferrin-Coated Brexpiprazole-Loaded Nanostructured Lipid Carriers for Brain Targeting. | AAPS PharmSciTech | 2026 | https://conductscience.org/library/papers/41872417 | PubMed |
| 41809261 | An erythrocyte membrane-fused plant-derived nanoparticles as a gene therapy vehicle for the treatment of CI/R injury. | Asian J Pharm Sci | 2025 | https://conductscience.org/library/papers/41809261 | PubMed |
| 41002483 | Development of an Innovative Nanosystem Based on Functionalized Albumin and Oxidized Gellan for the Synergistic Delivery of Curcumin and Temozolomide in the Treatment of Brain Cancer. | Gels | 2025 | https://conductscience.org/library/papers/41002483 | PubMed |
| 40869046 | Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer's Disease. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40869046 | PubMed |
| 40806198 | Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood-Brain Barrier and Blood-Tumor Barrier. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806198 | PubMed |
| 40573304 | Effect of Acoustic Pressure on Temozolomide-Loaded Oleic Acid-Based Liposomes and Its Safety to Brain Tissue. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40573304 | PubMed |
| 40313865 | The Confluence of Nanotechnology and Heat Shock Protein 70 in Pioneering Glioblastoma Multiforme Therapy: Forging Pathways Towards Precision Targeting and Transformation. | Adv Pharmacol Pharm Sci | 2025 | https://conductscience.org/library/papers/40313865 | PubMed |
| 40143051 | Targeting Neuroinflammation in Central Nervous System Diseases by Oral Delivery of Lipid Nanoparticles. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40143051 | PubMed |
| 40117096 | Anticancer potential of lactoferrin: effects, drug synergy and molecular interactions. | Biometals | 2025 | https://conductscience.org/library/papers/40117096 | PubMed |
| 39524922 | Temperature and Ultrasound-Responsive Nanoassemblies for Enhanced Organ Targeting and Reduced Cardiac Toxicity. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/39524922 | PubMed |
| 39403783 | Ionic liquids and their potential use in development and improvement of drug delivery systems: evidence of their tendency to promote drug accumulation in the brain. | Pharm Dev Technol | 2024 | https://conductscience.org/library/papers/39403783 | PubMed |
| 39337556 | A Novel Tetrahydroacridine Derivative with Potent Acetylcholinesterase Inhibitory Properties and Dissociative Capability against Aβ42 Fibrils Confirmed by In Vitro Studies. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337556 | PubMed |
| 38559959 | Lactoferrin Reduces Surfactant Content in the Self-Emulsifying Drug Delivery System. | ACS Omega | 2024 | https://conductscience.org/library/papers/38559959 | PubMed |
| 38275876 | Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38275876 | PubMed |
| 38013438 | Targeted Polymeric Nanoparticles as a Strategy for the Treatment of Glioblastoma: A Review. | Curr Drug Deliv | 2025 | https://conductscience.org/library/papers/38013438 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ITLN1 | 55600 | PubTator's text mining | https://conductscience.org/library/genes/55600 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28747713
GET https://conductscience.org/api/papers/v1/28747713/references?page=2